CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus

Multiple Sclerosis Journal

Volumn 17, Issue 2, 2011, Pages 151-156

  Warnke, Clemens ^a   Smolianov, Vsevolod ^a   Dehmel, Thomas ^a   Andrée, Marcel ^a   Hengel, Hartmut ^a   Zohren, Fabian ^a   Arendt, Gabriele ^a   Wiendl, Heinz ^b   Haas, Rainer ^a   Hartung, Hans Peter ^a   Adams, Ortwin ^a   Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Immunology; multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy; treatment

Indexed keywords

BETA INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE; VIRUS DNA;

ADULT; AGED; ARTICLE; CYTOMEGALOVIRUS; FEMALE; HEMATOPOIETIC STEM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JC VIRUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; STEM CELL MOBILIZATION; VIRUS LOAD; VIRUS REACTIVATION;

EID: 79951528852     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510385834     Document Type: Article

References (22)

1. Tan CS, Dezube BJ, Bhargava P., Autissier P., Wüthrich C., Miller J., et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 2009 ; 199: 881-888.
2. Cinque P., Koralnik IJ, Gerevini S., Miro JM and Price RW Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009 ; 9: 625-636.
3. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D., Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009 ; 113: 4834-4840.
4. Clifford DB, De Luca A., Simpson DM, Arendt G., Giovannoni G. and Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9: 438-446.
5. von Andrian UH and Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003 ; 348: 68-72. (Pubitemid 36026351)
6. Chen Y., Bord E., Tompkins T., Miller J., Tan CS, Kinkel RP, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009 ; 361: 1067-1074.
7. Major EO Reemergence of PML in natalizumab-treated patients - new cases, same concerns. N Engl J Med 2009 ; 361: 1041-1043.
8. Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L., Forrestal F., Sandrock AW and Goelz S. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010 ; 68: 304-310.
9. Warnke C., Adams O. and Kieseier BC Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009 ; 361: 2489 ; author reply 2489-2490.
10. Bonig H., Wundes A., Chang K., Lucas S. and Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008 ; 111: 3439-3441.
11. Zohren F., Toutzaris D., Klärner V., Hartung HP, Kieseier B. and Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008 ; 111: 3893-3895.
12. Jing D., Oelschlaegel U., Ordemann R., Hölig K., Ehninger G., Reichmann H., et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010 ; 45: 1489-1496.
13. Ransohoff RM Natalizumab and PML. Nat Neurosci 2005 ; 8: 1275. (Pubitemid 41630407)
14. Ryschkewitsch C., Jensen P., Hou J., Fahle G., Fischer S. and Major EO Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 2004 ; 121: 217-221. (Pubitemid 39295712)
15. Müller BT, Huber R., Henrich B., Adams O., Berns G., Siebler M., et al. Chlamydia pneumoniae, herpes simplex virus and cytomegalovirus in symptomatic and asymptomatic high-grade internal carotid artery stenosis. Does infection influence plaque stability? Vasa 2005 ; 34: 163-169. (Pubitemid 41248253)
16. Mendelson M., Monard S., Sissons P. and Sinclair J. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol 1996 ; 77: 3099-3102. (Pubitemid 27056530)
17. Iacobaeus E., Ryschkewitsch C., Gravell M., Khademi M., Wallstrom E., Olsson T., et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler 2009 ; 15: 28-35.
18. Verbeeck J., Van Assche G., Ryding J., Wollants E., Rans K., Vermeire S., et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 2008 ; 57: 1393-1397.
19. Sadiq SA, Puccio LM and Brydon EW JCV detection in multiple sclerosis patients treated with natalizumab. J Neurol 2010;257: 954-958.
20. Fedele CG, Ciardi MR, Delia S., Contreras G., Perez JL, De Oña M., et al. Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy. J Neurovirol 2003 ; 9: 551-558. (Pubitemid 37279371)
21. Van Assche G., Van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005 ; 353: 362-368. (Pubitemid 41132340)
22. Jilek S., Jaquiéry E., Hirsch HH, Lysandropoulos A., Canales M., Guignard L., et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010 ; 9: 264-272.